Novo Nordisk (NVO) USPTO patents

A drug delivery device is provided comprising or adapted to receive a cartridge with an axially displaceable piston.

The present invention provides a power unit (1) for a drug delivery device as well as methods for providing and mounting the power unit (1) in the drug delivery device.

The invention relates to a medical injection device having a needle cannula for multiple use and which needle cannula is cleaned between subsequent injections.

The present invention provides a drug injection device (100, 100′, 100″) comprising a first element (130) and a second element (102, 102′, 102″) configured to undergo movement relative to each other corresponding to an action performed on or by the drug injection device (100, 100′, 100″), wherein the first element (130) comprises serially disposed protrusions (133), and wherein the second element (102, 102′, 102″) comprises a second element base and a deflectable transducer (170, 170′, 170″).

The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.

A drug delivery system comprises an indicator element and a sensor system.

The invention relates to an injection system or a needle assembly in which a needle cannula secured to an injection device is shielded by a axially movable needle shield.

The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group.

The present invention relates to plasmids useful for prevention and/or delay of e.g. type 1 diabetes.

A drug delivery device is provided comprising or adapted to receive a cartridge with an axially displaceable piston.

A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided.

A syringe holder (200) comprising: a body (210) extending along a central longitudinal axis and adapted to receive the barrel (110) of a syringe (100), wherein the body (210) includes at least two body sections (240) disposed around the central longitudinal axis, the body sections (240, 240A, 240B) having distal ends with shoulder sections (250) adapted for being received in a circumferential gap (150) between the barrel (110) of the syringe (100) and a needle shield (120) covering a needle (130) of the syringe to retain the syringe (100) so as to prevent the syringe from moving distally (D) relative to the syringe holder (200), wherein the body (210) further comprises a plurality of expandable connector arrangements (230) each interconnecting pairs of the at least two body sections (240, 240A, 240B) so that the body sections (240, 240A, 240B) and the expandable connector arrangements (230) form a closed loop in the circumferential direction around the barrel (110) of a syringe (100) held by the body (210), wherein the expandable connector arrangements (230) are so configured that the body sections (240, 240A, 240B) are movable between a non-retaining position and a retaining position.

A drug delivery system comprises an indicator element and a sensor system.

The present invention provides a drug delivery device (1) comprising a drug delivery unit (10) comprising a dose expelling mechanism operable to expel a dose of drug from a drug reservoir (11), a cap (20) configured for dismountable mounting over a portion of the drug delivery unit (10), the cap (20) comprising a cavity (25, 26) for reception of the portion of the drug delivery unit (10), a seal (40) adapted to provide a sealing in an interface between the cap (20) and the drug delivery unit (10), a sensor system (30) configured to monitor internal pressure in the cavity (25, 26) and to register an event in response to sensing a change in the internal pressure which numerically exceeds a specified threshold level over a period of less than 5 seconds, and energy means (50) for powering the sensor system (30).

This invention relates to glucose-sensitive albumin-binding diboron conjugates.

A method of manufacturing one of a range of autoinjectors having cartridges (600, 600′, 600″) with different preset fill volumes, the method comprising the steps of: a) providing a front body assembly (100b, 100c, 100c′, 100c″), b) providing a cartridge (600, 600′, 600″) of given fill volume, c) providing a rear body assembly (100a) comprising a spring-driven drive ram assembly (310, 320) configured to drive the piston of a held cartridge (600, 600′, 600″), d) providing a ram spacer member (400, 400′, 400″), the ram spacer member defining a spacing geometry of length dimension (X1′, X1″, X1′″, XS′, XS″, XS′″, XR′, XR″, XR′″) selected according to the fill volume of the cartridge (600, 600′, 600″), and e) assembling a front body assembly (100b, 100c, 100c′, 100c″), the cartridge (600, 600′, 600″), the ram spacer member (400, 400′, 400″) and the rear body assembly (100a) so that the ram spacer member (400, 400′, 400″) is arranged axially between the drive ram assembly (310, 320) of the rear body assembly (100a) and the piston of a held cartridge (600, 600′, 600″).

The invention relates to a medical injection device having a polymeric housing or housing parts.

The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated.

Systems and methods are provided for adjusting a standing insulin medicament dosage regimen for a subject.

A drug delivery system comprises an indicator element and a sensor system.